Variations in mismatch repair genes predict prognosis in pancreatic cancer
While the treatment of heart failure has improved over the past two decades, a new study reported in the European Journal of Heart Failure finds that “the use of evidence-based treatments appears to be imbalanced according to the gender of the patient”. In particular, the study found that female patients were less frequently treated
Full Post: The drug treatment of heart failure is influenced by the gender of the patient and of the physician
Variations in mismatch repair genes can help predict treatment response and prognosis in patients with pancreatic cancer, according to research from The University of Texas M. D. Anderson Cancer Center presented today in advance of the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.
In the study, single nucleotide polymorphisms (SNPs) in genes involved in DNA mismatch repair were associated with response to gemcitabine (Gemzar)-based preoperative chemoradiation, tumor resectability (the likelihood of removing the entire tumor), and overall survival.
“Gemcitabine is a major chemotherapeutic agent used to treat pancreatic cancer, but we don’t understand why some patients respond and most patients do not,” said Donghui Li, Ph.D., the study’s lead author and professor in M. D. Anderson’s Department of Gastrointestinal Medical Oncology. “There has been no biomarker for pancreatic cancer used in the clinic to predict response. Our research interest has been to determine whether genetic variation in DNA repair can be a predictor of treatment response or a prognosis factor for patient survival.”
DNA repair is a complicated process, Li noted, with various mechanisms responsible for identifying and correcting different types of DNA damage. Mismatch repair genes correct mistakes in DNA replication or trigger cell death (apoptosis) if repair is not possible. Ensuring cell death is critical to preventing the runaway cell division that occurs in malignant tumors.
In the study, Li’s group obtained DNA samples from 154 patients with potentially resectable pancreatic adenocarcinomas who were participating in phase II clinical trials of preoperative gemcitabine-based chemoradiation. The researchers evaluated 15 SNPs (also called genotypes) among eight mismatch repair genes (EXO1, MLH1, MSH2, MSH3, MSH6, PMS1, TREX1, and TP73) and correlated them with tumor response to gemcitabine, the likelihood of achieving complete tumor resection, and overall survival.
Individually, five genotypes were associated with tumor response to preoperative gemcitabine-based chemoradiation; six were associated with tumor resectability, and ten were associated with overall survival. However, the combined effects of several genotypes on patient survival were dramatic. For example, 20 of 25 patients with 0 to 1 abnormal genotype were alive at the completion of the study (after a median follow-up time of 49.9 months). In contrast, median survival times were 36.2 months for patients with 2 adverse genotypes; 23.9 months for those with 3; 16.3 months for those with 4; 13 months for those with 5; and 8.3 months for those with 6 - 7.
If confirmed by other researchers, these findings could have a profound effect on how pancreatic cancer is treated. Having established biomarkers like abnormal mismatch repair genes, for example, would make choosing which patients might benefit from surgery much easier, Li explained.
“The doctor always faces a tough choice,” Li said. “Among the pancreatic tumors that are technically respectable, 25-30 percent might have very small tumors that have already metastasized to the liver or other organs. For these patients, the tumors recur very shortly after surgery, so these patients actually do not benefit from the traumatic and difficult surgery.”
The study results also suggest that variations in mismatch repair genes could be useful in determining which patients will respond best to gemcitabine-based chemoradiation. Having this information would allow physicians to move more quickly to give alternative drugs to a patient unlikely to respond to gemcitabine, Li explained.
“We hope that in the future we will be able to run a genetic test that will help doctors predict a patient’s outcome and help them select the best therapy for each patient,” Li concluded.
Abnormalities in genes that repair mistakes in DNA replication may help identify people who are at high risk of developing pancreatic cancer, a research team from The University of Texas M. D. Anderson Cancer Center reports in the Jan. 15 issue of Clinical Cancer Research. Defects in these critical DNA repair genes may act alone
Full Post: Defects in critical DNA repair genes may predict pancreatic cancer risk
Genetic variations in DNA repair patterns may increase risk of pancreatic cancer by as much as threefold or decrease it by as much as 77 percent, depending on the genes involved, according to a report published in the January 15, 2009, issue of Clinical Cancer Research, a journal of the American Association for Cancer Research.
Full Post: Genetic variations in DNA repair patterns may increase risk of pancreatic cancer
The use of chemotherapy following surgery reduces the risk of death from operable pancreatic cancer by around 30 per cent, says new research published in the British Journal of Cancer.Pancreatic cancer is the tenth most common cancer. Nearly 7,600 people are diagnosed with the disease in the UK each year. But, survival rates remain a
Full Post: Chemo boosts survival rates for pancreatic cancer
Pancreatic cancer is one of the deadliest and most difficult to treat cancers. Now, in a major step forward, researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center have shown that administering radiation therapy prior to surgery nearly doubles survival in pancreatic cancer patients with operable tumors. “Patients who received pre-surgical (neoadjuvant) radiation had almost double the
Full Post: New study on pancreatic cancer survival
UC Davis Cancer Center researchers have discovered a metabolic deficiency in pancreatic cancer cells that can be used to slow the progress of the deadliest of all cancers. Published in the October issue of the International Journal of Cancer , study results indicate that pancreatic cancer cells cannot produce the amino acid arginine, which plays
Full Post: Researchers discover metabolic deficiency in pancreatic cancer